Physician profile
Chad Hill
NPI 1861503062
$1,866.25
in general payments reported to CMS, 2019-2025
22 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $93.68 · 2021: $401 · 2022: $513 · 2023: $347 · 2024: $210 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.45 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $699.67 | 2019-2024 | |
| Organon LLC | $238.05 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $137.49 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $114.20 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.24 | 2019-2025 | |
| Pfizer INC. | $105.65 | 2019-2023 | |
| Hologic Sales and Service, LLC | $97.13 | 2020-2023 | Novasure, Coolseal Generator, Myosure Tissue Removal Device |
| Millicent US INC | $70.05 | 2025 | Femlyv, Intrarosa |
| Exeltis, USA INC. | $63.29 | 2021-2023 | Slynd |
| Therapeuticsmd, INC. | $38.89 | 2019-2022 | |
| Meditrina | $27.78 | 2022 | |
| Medtronic, INC. | $17.97 | 2023 | Ligasure |
| Axonics, INC. | $17.69 | 2023 | Bulkamid |
| Myovant Sciences INC. | $17.40 | 2022 | |
| Coloplast Corp | $16.01 | 2023 | Altis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $15.21 | 2025 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $15.05 | 2023 | Exparel |
| Avion Pharmaceuticals | $14.23 | 2022 | |
| Evofem Biosciences, INC. | $14.05 | 2022 | |
| Shield Therapeutics INC | $13.91 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $13.33 | 2020 | |
| Lupin INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.